NCT07161713 SBU-RESET: RElaxation, Stress Reduction and Epigenetics Trial in Cancer Survivors
| NCT ID | NCT07161713 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Barbara Nemesure |
| Condition | Cancer Survivors |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2025-09-17 |
| Primary Completion | 2027-09-17 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2025-09-17 with a primary completion date of 2027-09-17.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Cancer survivors can experience health issues that cause chronic illness and lower quality of life. Yoga is a well-known holistic approach to health and overall well-being. Mindfulness has many benefits, including improved focus and less stress. This study aims to evaluate if yoga and/or mindfulness has a positive effect on cancer survivors social, emotional and physical well-being as well as their epigenetics. Epigenetics is how the environment can effect your genes; not by changing our DNA, but by turning genes on or off.
Eligibility Criteria
Inclusion Criteria: * Adults over 18 years old * Primary diagnosis: Lung Cancer, Colon Cancer and Non-Hodgkin's lymphoma (NHL) * Six months post cancer-directed treatment (chemotherapy, targeted and immunotherapy). Patients with active disease (e.g. metastatic colorectal cancer) who are not receiving any cancer-directed treatment are eligible. * Able to provide a saliva sample * Gives informed consent and agrees to be randomly assigned * Able to complete the questionnaire(s) in English. Exclusion Criteria: * Adults with primary anal and/or primary rectal cancer. * Adult cancer survivors who are currently on an active treatment regimen. * Oral or any pathological conditions that can limit the ability to produce saliva. * Unable to participate in full length study period and follow up thereafter. * Is pregnant or plan to become pregnant during the study period. * Currently practicing yoga or SMART * Those on corticosteroid therapy. * Documented fall or syncope within the last 6 months
Contact & Investigator
Stony Brook Cancer Center Clinical Trials
✉ CancerClinicalTrials@stonybrookmedicine.edu📞 631-728-7425
Barbara Nemesure, PhD
PRINCIPAL INVESTIGATOR
Stony Brook University
Frequently Asked Questions
Who can join the NCT07161713 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cancer Survivors. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07161713 currently recruiting?
Yes, NCT07161713 is actively recruiting participants. Contact the research team at CancerClinicalTrials@stonybrookmedicine.edu for enrollment information.
Where is the NCT07161713 trial being conducted?
This trial is being conducted at Stony Brook, United States.
Who is sponsoring the NCT07161713 clinical trial?
NCT07161713 is sponsored by Barbara Nemesure. The principal investigator is Barbara Nemesure, PhD at Stony Brook University. The trial plans to enroll 100 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.